Price Alert

Ostin Technology Group Co... (OST)

NASDAQ: OST · Real-Time Price · USD

1.53

-0.11 (-6.71%)

At close: Sep 03, 2025, 3:59 PM

1.59

3.92%

Pre-market: Sep 04, 2025, 07:20 AM EDT

-6.71% (1D)

Bid	1.56
Market Cap	8.1M
Revenue (ttm)	32.46M
Net Income (ttm)	-10.06M
EPS (ttm)	-235.75
PE Ratio (ttm)	-0.01
Forward PE	n/a
Analyst	n/a

Ask	1.66
Volume	110,936
Avg. Volume (20D)	793,604
Open	1.63
Previous Close	1.64
Day's Range	1.53 - 1.64
52-Week Range	1.35 - 235.00
Beta	0.67

About OST

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol OST

Website n/a

Full Company Profile

Why Price Moved

1 month ago

-13.95%

Ostin Technology shares are trading lower. The com... Unlock content with Pro Subscription

2 months ago

-54.69%

Ostin Technology Group shares are trading lower. The company announced a $5 million registered direct offering.

News

1 day ago · newsfilecorp.com

OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting

Company on track to begin submission of a rolling Biologics Licensing Application (BLA) request for OST-HER2 to U.S. Food & Drug Administration in September 2025 New York, New York--(Newsfile Corp. - ...

1 week ago · newsfilecorp.com

OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025

New York, New York--(Newsfile Corp. - August 27, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate bi...

2 weeks ago · newsfilecorp.com

OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

U.S. FDA ("FDA") confirms OST-HER2 meets biological definition of Regenerative Medicine Advanced Therapy (RMAT) FDA issues OST-HER2 BLA number in preparation for Accelerated Approval submission follow...

3 weeks ago · newsfilecorp.com

OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

MHRA seeks to harmonize UK & US regulatory review via Project Orbis EMA Rapporteur Scientific Advice Meeting scheduled for October 2025 New York, New York--(Newsfile Corp. - August 7, 2025) - OS Thera...